Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis

The purpose of this study is to monitor the long-term safety of ustekinumab in pediatric participants (6 years to 17 years of age at the time of inclusion) with moderate to severe plaque

body mass index
ustekinumab
plaque psoriasis
cancer
autoimmune disease
  • 50 views
  • 15 Jul, 2021
  • 48 locations
Swiss Dermatology Network of Targeted Therapies (SDNTT)

, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of

cyclosporine
methotrexate
infliximab
puva
etanercept
  • 14 views
  • 26 Jan, 2021
  • 6 locations
Psoriasis Longitudinal Assessment and Registry

The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis. The study also includes patients

cyclosporine
ixekizumab
acitretin
arthritis
secukinumab
  • 4040 views
  • 07 Sep, 2021
  • 494 locations
PsoBest - The German Psoriasis Registry

Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments has been shown in clinical …

cyclosporine
biological treatment
methotrexate
antipsoriatics
etanercept
  • 59 views
  • 22 Jan, 2021
  • 1 location
Spanish Registry of Systemic Treatments in Psoriasis

The purpose of Biobadaderm is a to study the safety of systemic therapy in psoriasis.

systemic therapy
  • 45 views
  • 23 Jan, 2021
  • 13 locations
Changes in Body Composition Under Ustekinumab in PsA

, cardiovascular risk and resistance to the insulin). In addition, data on changes in body composition and bone mineral density were not available under a new psA treatment, namely ustekinumab (anti-IL12

ustekinumab
arthritis
rheumatoid arthritis
  • 0 views
  • 25 Jan, 2021
  • 2 locations
Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)

The purpose of post-marketing surveillance (PMS) is to assess the safety and effectiveness of ustekinumab (Stelara) for Crohn's disease participants under real world clinical practice.

crohn's disease
ustekinumab
  • 8 views
  • 16 Aug, 2021
  • 42 locations
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases

The purpose of this study is to assess the effectiveness of ustekinumab on extra-intestinal manifestations (EIMs) and immune-mediated inflammatory diseases (IMIDs) associated with inflammatory

crohn's disease
corticosteroids
ustekinumab
ulceration
mercaptopurine
  • 15 views
  • 13 Aug, 2021
  • 2 locations
Inflammatory Cells From Various Pathologies

The objective of this experiment is to develop and validate in vitro methods to isolate inflammatory cells from skin biopsies for quantitative flow cytometry analysis. Real-time polymerase chain reaction (RT-PCR) will also be performed using skin biopsy samples to validate flow cytometry results. Such methods could eventually be used to …

serum ige
rosacea
skin biopsy
atopic dermatitis
systemic sclerosis
  • 156 views
  • 29 Aug, 2021
  • 1 location
Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients

The purpose of this study is to study the risk of hepatitis flare in patients with previous hepatitis B virus exposure amongst patients on immunosuppressive and biological modifier therapies

immunosuppressive agents
  • 0 views
  • 11 Aug, 2021
  • 1 location